Opinion

Video

Acute Myeloid Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

Author(s):

Elias Jabbour, MDJames M. Foran, MD

Following the ASCO 2023 and EHA 2023 Annual Meetings, experts discuss important updates in acute myeloid leukemia.

Related Videos
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School
Sattva S. Neelapu, MD
Sattva S. Neelapu, MD
Julie M. Vose, MD, MBA
Lakshmi Nayak, MD
John Burke, MD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Ben Levy, MD, and Yan Leyfman, MD
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Carrie L. Kitko, MD
Related Content
Kathleen A. Dorritie, MD, of University of Pittsburgh Medical Center Hillman Cancer Center​
June 11th 2024

Long-Term Data for Up-Front Combinations Reaffirm Treatment Options in CLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Angelos Stergiou, MD, ScD hc
June 10th 2024

CDK9 Inhibitor SLS009 Displays Activity in Relapsed/Refractory AML

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Eunice S. Wang, MD
June 6th 2024

Wang Expands on the Continued Investigation of Targeted Therapies in Relapsed/Refractory AML

Mark Frattini, MD, PhD
June 5th 2024

UCART22 Earns Orphan Drug Designation for Acute Lymphoblastic Leukemia in Europe